On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
Personalised medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most promising tools. This innovative approach, which involves genetically modifying the cells of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results